No Data
Zhuzhou Qianjin Pharmaceutical (600479.SH): The tadalafil tablets have received a notification of approval for the supplemental application for the Pharmaceutical.
On January 20, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the approval notice from the National Medical Products Administration for the supplementary application of Tadalafil tablets (5mg). Tadalafil tablets are a type 5 phosphodiesterase (PDE5) inhibitor developed by Eli Lilly and Co, with the brand name Cialis, and are a first-line treatment for male erectile dysfunction. With the continuous in-depth clinical research, the National Medical Products Administration has approved the indication for Tadalafil new tablets for benign prostatic hyperplasia.
ZhuZhou QianJin Pharmaceutical Unit Gets China Nod for Premature Ejaculation Tablets; Shares Fall 3%
Zhuzhou Qianjin Pharmaceutical (600479.SH): Dapoxetine hydrochloride tablets have obtained the Pharmaceutical registration certificate.
On December 12, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., received the drug registration certificate for Dapoxetine Hydrochloride Tablets approved by the National Medical Products Administration. Dapoxetine is a selective serotonin reuptake inhibitor that binds to and blocks the serotonin reuptake receptors on the presynaptic membrane, increasing the concentration of serotonin in the synapse, achieving the effect of delaying ejaculation.
Zhuzhou Qianjin Pharmaceutical (600479.SH): Currently, there are no drugs for the auxiliary treatment of AIDS.
Gelonghui reported on December 10 that Zhuzhou Qianjin Pharmaceutical (600479.SH) stated on the investor interaction platform that the company currently has no drugs for the auxiliary treatment of AIDS.
Zhuzhou Qianjin Pharmaceutical (600479.SH): Recently, the sales of hygiene products have shown a growth trend.
gelonhui on November 27th | Zhuzhou Qianjin Pharmaceutical (600479.SH) stated on the investor interaction platform that in the third quarter of 2024, the sales proportion of health products was 3.48%, and recently the sales of health products have been growing.
Is ZhuZhou QianJin PharmaceuticalLtd (SHSE:600479) A Risky Investment?